“We are really not expecting to see widespread vaccination until the middle of next year,” Harris told.
According to her, any vaccine-candidate showed a ‘clear signal’ about at least 50% efficiency during the clinical trials.
“A lot of people have been vaccinated and what we don’t know whether the vaccine works…at this stage we do not have the clear signal of whether or not it has the level of worthwhile efficacy and safety,” Harris added.
On August 11, President of Russia Vladimir Putin reported that the first vaccine against coronavirus was registered in Russia.
It is noted that the vaccine would be produced by N. F. Gamaleya Federal Research Center for Epidemiology & Microbiology and Russian Binnopharm Company. According to Murashko, finalizing takes place of the technical regulations for scaling of production at the number of Russian productions.
Later, China reported registering its first vaccine against coronavirus. It is stated that the application for the patent was filed in March but it was approved only now. The patent is issued by the National Intellectual Property Administration.